Proto-Oncogene Proteins c-met
"Proto-Oncogene Proteins c-met" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cell surface protein-tyrosine kinase receptors for HEPATOCYTE GROWTH FACTOR. They consist of an extracellular alpha chain which is disulfide-linked to the transmembrane beta chain. The cytoplasmic portion contains the catalytic domain and sites critical for the regulation of kinase activity. Mutations in the c-met proto-oncogene are associated with papillary renal carcinoma and other neoplasia.
| Descriptor ID |
D019859
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.075 D12.776.543.750.630.186 D12.776.543.750.750.400.100 D12.776.624.664.700.186
|
| Concept/Terms |
Proto-Oncogene Proteins c-met- Proto-Oncogene Proteins c-met
- Proto Oncogene Proteins c met
- MET Receptor Tyrosine Kinase
- c-Met Receptor Tyrosine Kinase
- c Met Receptor Tyrosine Kinase
- Receptor, Hepatocyte Growth Factor
- met Proto-Oncogene Proteins
- Proto-Oncogene Proteins, met
- met Proto Oncogene Proteins
- Scatter Factor Receptor
- Receptor, HGF
- HGF Receptor
- Hepatocyte Growth Factor Receptor
- c-met Proteins
- c met Proteins
- MET Proto-Oncogene, Receptor Tyrosine Kinase
- MET Proto Oncogene, Receptor Tyrosine Kinase
- Receptor, Scatter Factor
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-met".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-met".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-met" by people in this website by year, and whether "Proto-Oncogene Proteins c-met" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2002 | 2 | 0 | 2 |
| 2003 | 3 | 2 | 5 |
| 2004 | 2 | 0 | 2 |
| 2005 | 3 | 0 | 3 |
| 2006 | 1 | 0 | 1 |
| 2007 | 11 | 2 | 13 |
| 2008 | 3 | 3 | 6 |
| 2009 | 7 | 3 | 10 |
| 2010 | 7 | 2 | 9 |
| 2011 | 8 | 2 | 10 |
| 2012 | 2 | 0 | 2 |
| 2013 | 9 | 0 | 9 |
| 2014 | 8 | 0 | 8 |
| 2015 | 2 | 2 | 4 |
| 2016 | 3 | 2 | 5 |
| 2017 | 3 | 0 | 3 |
| 2018 | 2 | 1 | 3 |
| 2019 | 2 | 1 | 3 |
| 2020 | 4 | 2 | 6 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-met" by people in Profiles.
-
Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma. Clin Cancer Res. 2021 11 01; 27(21):5781-5792.
-
Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report. Cold Spring Harb Mol Case Stud. 2020 12; 6(6).
-
Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. J Clin Oncol. 2020 11 01; 38(31):3672-3684.
-
MET receptor in oncology: From biomarker to therapeutic target. Adv Cancer Res. 2020; 147:259-301.
-
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med. 2020 09 03; 383(10):931-943.
-
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping. Cancer Treat Rev. 2020 Jul; 87:102022.
-
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors. Mol Cancer Ther. 2020 05; 19(5):1210-1217.
-
First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. Clin Cancer Res. 2020 03 15; 26(6):1237-1246.
-
Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer. Future Oncol. 2020 Jan; 16(1):4289-4301.
-
Meta-analysis of functional expression and mutational analysis of c-Met in various cancers. Curr Probl Cancer. 2020 08; 44(4):100515.